BRPI1011683A2 - derivado isoquinolina substituída - Google Patents

derivado isoquinolina substituída

Info

Publication number
BRPI1011683A2
BRPI1011683A2 BRPI1011683A BRPI1011683A BRPI1011683A2 BR PI1011683 A2 BRPI1011683 A2 BR PI1011683A2 BR PI1011683 A BRPI1011683 A BR PI1011683A BR PI1011683 A BRPI1011683 A BR PI1011683A BR PI1011683 A2 BRPI1011683 A2 BR PI1011683A2
Authority
BR
Brazil
Prior art keywords
isoquinoline derivative
substituted isoquinoline
substituted
derivative
isoquinoline
Prior art date
Application number
BRPI1011683A
Other languages
English (en)
Inventor
Hiroyoshi Hidaka
Kengo Sumi
Kouichi Takahashi
Ryohei Nakamura
Yoshihiro Inoue
Original Assignee
Western Therapeutics Inst Inc D
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Western Therapeutics Inst Inc D filed Critical Western Therapeutics Inst Inc D
Publication of BRPI1011683A2 publication Critical patent/BRPI1011683A2/pt
Publication of BRPI1011683B1 publication Critical patent/BRPI1011683B1/pt
Publication of BRPI1011683B8 publication Critical patent/BRPI1011683B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI1011683A 2009-06-19 2010-06-18 derivados de isoquinolina substituída, suas composições farmacêuticas e seus usos BRPI1011683B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009-146040 2009-06-19
JP2009146040 2009-06-19
PCT/JP2010/004101 WO2010146881A1 (ja) 2009-06-19 2010-06-18 置換されたイソキノリン誘導体

Publications (3)

Publication Number Publication Date
BRPI1011683A2 true BRPI1011683A2 (pt) 2016-03-22
BRPI1011683B1 BRPI1011683B1 (pt) 2020-10-20
BRPI1011683B8 BRPI1011683B8 (pt) 2021-05-25

Family

ID=43356211

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1011683A BRPI1011683B8 (pt) 2009-06-19 2010-06-18 derivados de isoquinolina substituída, suas composições farmacêuticas e seus usos

Country Status (19)

Country Link
US (1) US8951997B2 (pt)
EP (1) EP2444395B1 (pt)
JP (1) JP4915010B2 (pt)
KR (1) KR101732907B1 (pt)
CN (1) CN102448941B (pt)
AU (1) AU2010261206B2 (pt)
BR (1) BRPI1011683B8 (pt)
CA (1) CA2764124C (pt)
CY (1) CY1117157T1 (pt)
DK (1) DK2444395T3 (pt)
EA (1) EA019523B1 (pt)
ES (1) ES2560603T3 (pt)
HR (1) HRP20160096T1 (pt)
HU (1) HUE028684T2 (pt)
MX (1) MX2011013857A (pt)
NZ (1) NZ596615A (pt)
PL (1) PL2444395T3 (pt)
TW (1) TWI527798B (pt)
WO (1) WO2010146881A1 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
WO2010126626A2 (en) 2009-05-01 2010-11-04 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
BR112013015604B1 (pt) 2010-12-22 2021-11-03 D. Western Therapeutics Institute, Inc Derivado de isoquinolina-6-sulfonamida, composição farmacêutica compreendendo o mesmo e uso do dito composto para tratar ou prevenir glaucoma, hipertensão ocular ou doença cardiovascular
JP2013035802A (ja) * 2011-08-10 2013-02-21 D Western Therapeutics Institute Inc 緑内障又は高眼圧症の予防又は治療剤
ES2776199T3 (es) 2013-03-15 2020-07-29 Aerie Pharmaceuticals Inc Conjugados de compuestos de isoquinolina y prostaglandinas
JP5557408B1 (ja) * 2013-04-24 2014-07-23 国立大学法人九州大学 眼底疾患治療剤
CN105085478B (zh) * 2014-04-28 2019-04-12 南京明德新药研发股份有限公司 异喹啉磺胺衍生物及其药物组合物和制药用途
CN105906609A (zh) * 2016-05-19 2016-08-31 武昌理工学院 一种1,4-二氮杂环庚烷衍生物的制备方法
CN113912586B (zh) 2016-08-31 2023-04-07 江苏恒瑞医药股份有限公司 氧代吡啶酰胺类衍生物、其制备方法及其在医药上的应用
WO2018045091A1 (en) 2016-08-31 2018-03-08 Aerie Pharmaceuticals, Inc. Ophthalmic compositions
US9840468B1 (en) 2016-12-30 2017-12-12 Aerie Pharmaceuticals, Inc. Methods for the preparation of 6-aminoisoquinoline
CA3057872A1 (en) 2017-03-31 2018-10-04 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
CN109134433B (zh) * 2017-06-16 2021-05-25 成都先导药物开发股份有限公司 一种抑制rock的化合物及其应用
CN108929270B (zh) * 2018-08-15 2021-06-08 上海罕道医药科技有限公司 一种药物中间体双取代含氮杂环的胺类化合物的合成
AU2019337703B2 (en) 2018-09-14 2023-02-02 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
JPWO2020091054A1 (ja) * 2018-11-01 2021-12-09 株式会社デ・ウエスタン・セラピテクス研究所 1,4−ジアゾカン化合物又はその塩
ES3010713T3 (en) 2018-12-18 2025-04-04 D Western Therapeutics Inst Inc Isoquinoline sulfonyl chloride acid addition salts and method of manufacture thereof
CN116194448A (zh) 2020-08-31 2023-05-30 视点医疗股份有限公司 用于治疗眼科疾病的化合物和制剂
AU2024402833A1 (en) 2023-12-19 2026-06-18 D. Western Therapeutics Institute, Inc. Pharmaceutical composition for preventing/treating ocular complication in chronic graft-versus-host disease

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4456757A (en) 1981-03-20 1984-06-26 Asahi Kasei Kogyo Kabushiki Kaisha Isoquinolinesulfonyl derivatives and process for the preparation thereof
JPS5993054A (ja) 1982-11-18 1984-05-29 Asahi Chem Ind Co Ltd イソキノリンスルホン酸アミド誘導体
US4678783B1 (en) 1983-11-04 1995-04-04 Asahi Chemical Ind Substituted isoquinolinesulfonyl compounds
JPH0667926B2 (ja) 1985-11-12 1994-08-31 旭化成工業株式会社 環状のイソキノリンスルホンアミド誘導体
JPH0215067A (ja) 1988-07-04 1990-01-18 Hokuriku Seiyaku Co Ltd イソキノリンスルホンアミド誘導体
US5245034A (en) 1988-12-26 1993-09-14 Kiroyoshi Hidaka Compound having vessel smooth muscle relaxation activity
US5216150A (en) 1988-12-26 1993-06-01 Hiroyoshi Hidaka Derivatives of isoquinoline (and naphthalene) sulfonamides
JPH069402A (ja) 1991-05-15 1994-01-18 Hiroyoshi Hidaka 抗潰瘍剤
PT885888E (pt) 1996-02-02 2003-12-31 Western Therapeutics Inst D Derivados e farmacos de isoquinolina
EP1395257A1 (en) * 2001-06-12 2004-03-10 Elan Pharmaceuticals, Inc. Macrocycles useful in the treatment of alzheimer's disease
WO2005080394A1 (en) 2004-02-24 2005-09-01 Bioaxone Therapeutique Inc. 4-substituted piperidine derivatives
US20050272723A1 (en) 2004-04-27 2005-12-08 The Regents Of The University Of Michigan Methods and compositions for treating diseases and conditions associated with mitochondrial function
US7517991B2 (en) 2004-10-12 2009-04-14 Bristol-Myers Squibb Company N-sulfonylpiperidine cannabinoid receptor 1 antagonists
CA2610166C (en) 2005-04-25 2010-07-27 D. Western Therapeutics Institute, Inc. Benzoquinolinesulfonamide derivatives useful as rho-kinase inhibitors
WO2006115244A1 (ja) 2005-04-25 2006-11-02 D. Western Therapeutics Institute, Inc. 4-ブロモイソキノリン誘導体及びこれを含有する医薬
AU2006285915B2 (en) 2005-08-30 2011-02-24 Asahi Kasei Pharma Corporation Sulfonamide compound
US20080064681A1 (en) 2006-09-11 2008-03-13 Hiroyoshi Hidaka Therapeutic agent for treating glaucoma
BRPI0720710A2 (pt) 2006-12-27 2014-12-23 Sanofi Aventis Derivados de isoquinolona e isoquinolinona substituídos com cicloalquilamina
AU2007338410B2 (en) 2006-12-27 2012-08-16 Sanofi-Aventis Cycloalkylamine substituted isoquinoline derivatives
CA2679263A1 (en) 2007-02-28 2008-09-04 Asahi Kasei Pharma Corporation Sulfonamide compound

Also Published As

Publication number Publication date
ES2560603T3 (es) 2016-02-22
TWI527798B (zh) 2016-04-01
BRPI1011683B8 (pt) 2021-05-25
US8951997B2 (en) 2015-02-10
TW201100385A (en) 2011-01-01
DK2444395T3 (en) 2016-03-14
US20120035159A1 (en) 2012-02-09
WO2010146881A1 (ja) 2010-12-23
BRPI1011683B1 (pt) 2020-10-20
EP2444395A4 (en) 2012-11-28
KR20120069609A (ko) 2012-06-28
EA019523B1 (ru) 2014-04-30
EP2444395A1 (en) 2012-04-25
CY1117157T1 (el) 2017-04-05
EP2444395B1 (en) 2016-01-06
NZ596615A (en) 2013-07-26
KR101732907B1 (ko) 2017-05-08
MX2011013857A (es) 2012-01-30
CA2764124A1 (en) 2010-12-23
PL2444395T3 (pl) 2016-06-30
CN102448941B (zh) 2016-04-06
CN102448941A (zh) 2012-05-09
AU2010261206B2 (en) 2015-10-08
EA201171328A1 (ru) 2012-05-30
JP4915010B2 (ja) 2012-04-11
HUE028684T2 (en) 2016-12-28
CA2764124C (en) 2016-12-13
HRP20160096T1 (hr) 2016-02-26
AU2010261206A1 (en) 2011-12-15
JPWO2010146881A1 (ja) 2012-12-06

Similar Documents

Publication Publication Date Title
EP2433940A4 (en) SPIROIMIDAZOLONDERIVAT
BRPI1008774A2 (pt) espiroamida substituída
ECSP12011999A (es) Derivados benzamida sustituidos
EP2404918A4 (en) pyridine
BRPI1013246A2 (pt) derivados de benzofuralina
BR112012002828A2 (pt) derivados de 5-fluorpirimidinona
DE112010004215A5 (de) Hydrostataktor
EP2397480A4 (en) DIAZEPINEDIONEDERIVATE
EP2444395A4 (en) SUBSTITUTED ISOCHINOLINE DERIVATIVE
BRPI1008827A2 (pt) deisobutenizador
BRPI1013844A2 (pt) derivados de piridina-isoxazol
DE112010002728A5 (de) Turboinhalator
DE112010004249A5 (de) Spindelaktor
BRPI1014454A2 (pt) derivados de isoxazol-pirazol
BR112012002810A2 (pt) derivados de n1-acil-5-fluoropirimidinona
DE112009005462T8 (de) Lenkungsssteuervorrichtung
BRPI1008070A2 (pt) tricianoboratos
DK2387580T3 (da) Deoxyactagardinderivater
EP2401281A4 (en) PYRIMIDINPYRIMIDOINDAZOLDERIVAT
BRPI1007369A2 (pt) derivados de di-hidroquinolinona
EP2492266A4 (en) 5-hydroxypyrimidine-4-carboxamide
BRPI1011416A2 (pt) derivados de antraquinova novos
DE112010004865T8 (de) Lamellennassreibkupplung
BRPI1010159A2 (pt) bistuti
EP2448583A4 (en) Substituted 4-hydroxypyrimidine-5-carboxamides

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Notification to applicant to reply to the report for non-patentability or inadequacy of the application [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 20/10/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/06/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF